Diagnostic Accuracy of Immunochromatographic Fecal Calprotectin Assay Evaluated
By LabMedica International staff writers Posted on 20 Mar 2016 |
Fecal calprotectin is a noninvasive marker for bowel diseases and it is of high value for following disease activity in Crohn's disease (CD) and ulcerative colitis (UC).
The diagnostic performance of the recently introduced immunochromatographic assay has been evaluated in comparison to the well-known enzyme-linked immunosorbent assay (ELISA) tests for calprotectin assay to obtain a rapid diagnosis of bowel inflammation in pediatric patients.
Scientists at the Burlo Garofolo Pediatric Institute (Trieste, Italy) obtained fecal samples from 148 pediatric subjects ranging in ages from 2 to 18 years, 70 were males and 78 were females, 44 of which were affected by intestinal diseases. The pediatric subjects included 104 healthy subjects, 29 with and Crohn’s disease (CD), and 15 with Ulcerative colitis (UC). All patients were diagnosed in acute phase. All stool samples were collected in plastic containers and frozen at -20 °C without urine contamination.
The commercial kits used were the PhiCal Calprotectin ELISA based on two-site sandwich technique with two selected monoclonal antibodies, cutoff of 50 mg/kg (Pantec Immunodiagnostic; Milan, Italy); Calprest ELISA based on polyclonal antibodies against fecal calprotectin, cutoff of 100 mg/kg (Eurospital; Trieste, Italy); and Eurospital’s CalFast Immunochromatographic assay with a cutoff of 100 mg/kg combined with a mixture of anti-calprotectin polyclonal and monoclonal antibodies. Once extracted, the sample is diluted and transferred into the diagnostic device. A dedicated reader provides the concentration of calprotectin in the sample in just 15 minutes.
The scientists found that the sensitivity and specificity of CalFast, CalPrest, and PhiCal were 86.4%, 88.6%, and 93.2% and 86.6%, 74%, and 64.4%, respectively. The area under the curve, obtained from receiver operating characteristic analysis, indicated the lack of significant difference among all the kits used. The authors concluded that the immunochromatographic assay demonstrated good diagnostic predictive values, comparable to those of the ELISA methods, and may represent a valid alternative in order to save operators' time. The test, in fact, has a short turnaround time and does not need a specific ELISA instrumentation. The study was published on February 15, 2016, in the Journal of Clinical Laboratory Analysis.
Related Links:
Burlo Garofolo Pediatric Institute
Pantec Immunodiagnostic
Eurospital
The diagnostic performance of the recently introduced immunochromatographic assay has been evaluated in comparison to the well-known enzyme-linked immunosorbent assay (ELISA) tests for calprotectin assay to obtain a rapid diagnosis of bowel inflammation in pediatric patients.
Scientists at the Burlo Garofolo Pediatric Institute (Trieste, Italy) obtained fecal samples from 148 pediatric subjects ranging in ages from 2 to 18 years, 70 were males and 78 were females, 44 of which were affected by intestinal diseases. The pediatric subjects included 104 healthy subjects, 29 with and Crohn’s disease (CD), and 15 with Ulcerative colitis (UC). All patients were diagnosed in acute phase. All stool samples were collected in plastic containers and frozen at -20 °C without urine contamination.
The commercial kits used were the PhiCal Calprotectin ELISA based on two-site sandwich technique with two selected monoclonal antibodies, cutoff of 50 mg/kg (Pantec Immunodiagnostic; Milan, Italy); Calprest ELISA based on polyclonal antibodies against fecal calprotectin, cutoff of 100 mg/kg (Eurospital; Trieste, Italy); and Eurospital’s CalFast Immunochromatographic assay with a cutoff of 100 mg/kg combined with a mixture of anti-calprotectin polyclonal and monoclonal antibodies. Once extracted, the sample is diluted and transferred into the diagnostic device. A dedicated reader provides the concentration of calprotectin in the sample in just 15 minutes.
The scientists found that the sensitivity and specificity of CalFast, CalPrest, and PhiCal were 86.4%, 88.6%, and 93.2% and 86.6%, 74%, and 64.4%, respectively. The area under the curve, obtained from receiver operating characteristic analysis, indicated the lack of significant difference among all the kits used. The authors concluded that the immunochromatographic assay demonstrated good diagnostic predictive values, comparable to those of the ELISA methods, and may represent a valid alternative in order to save operators' time. The test, in fact, has a short turnaround time and does not need a specific ELISA instrumentation. The study was published on February 15, 2016, in the Journal of Clinical Laboratory Analysis.
Related Links:
Burlo Garofolo Pediatric Institute
Pantec Immunodiagnostic
Eurospital
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form